Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL

Estimated four-year event-free survival significantly higher in patients receiving blinatumomab versus traditional chemotherapy
child cancer chemotherapy
Adobe Stock
Medically Reviewed By:
Farrokh Sohrabi, M.D.
Published on
Updated on
Loading content, please wait...
logo
www.healthday.com